Death or Neurodevelopmental Impairment at 18 to 22 Months Corrected Age in a Randomized Trial of Early Dexamethasone to Prevent Death or Chronic Lung Disease in Extremely Low Birth Weight Infants

Objective To evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18-22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants. Study design Evaluation of infants at 18-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of pediatrics 2014, Vol.164 (1), p.34-39.e2
Hauptverfasser:	Stark, Ann R., MD, Carlo, Waldemar A., MD, Vohr, Betty R., MD, Papile, Lu Ann, MD, Saha, Shampa, PhD, Bauer, Charles R., MD, Oh, William, MD, Shankaran, Seetha, MD, Tyson, Jon E., MD, MPH, Wright, Linda L., MD, Poole, W. Kenneth, PhD, Das, Abhik, PhD, Stoll, Barbara J., MD, Fanaroff, Avroy A., MD, Korones, Sheldon B., MD, Ehrenkranz, Richard A., MD, Stevenson, David K., MD, Peralta-Carcelen, Myriam, MD, MPH, Wilson-Costello, Deanne E., MD, Bada, Henrietta S., MD, Heyne, Roy J., MD, Johnson, Yvette R., MD, MPH, Lee, Kimberly Gronsman, MD, Steichen, Jean J., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Cause of Death - trends Child Development Chronic Disease Developmental Disabilities - epidemiology Developmental Disabilities - etiology Developmental Disabilities - prevention & control Dexamethasone - administration & dosage Dose-Response Relationship, Drug Double-Blind Method Follow-Up Studies Glucocorticoids - administration & dosage Humans Incidence Infant Infant, Extremely Low Birth Weight Injections, Intravenous Lung Diseases - complications Lung Diseases - epidemiology Lung Diseases - prevention & control Neurologic Examination Pediatrics Retrospective Studies Survival Rate - trends Time Factors Treatment Outcome United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective To evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18-22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants. Study design Evaluation of infants at 18-22 months corrected age included anthropomorphic measurements, a standard neurological examination, and the Bayley Scales of Infant Development-II, including the Mental Developmental Index and the Psychomotor Developmental Index. NDI was defined as moderate or severe cerebral palsy, Mental Developmental Index or Psychomotor Developmental Index
ISSN:	0022-3476 1097-6833 1097-6833
DOI:	10.1016/j.jpeds.2013.07.027